Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan, ROC; Division of Urology, Department of Surgery, Taipei Veterans General Hospital and Su-Ao/Yuan-Shan Branch, Yi-Lan, Taiwan, ROC.
J Chin Med Assoc. 2013 Nov;76(11):599-605. doi: 10.1016/j.jcma.2013.07.007. Epub 2013 Aug 9.
Induced pluripotent stem cells (iPSCs) are generated by reprogramming somatic cells to a pluripotent state by the introduction of specific factors. They can be generated from cells of different origins, such as fibroblasts, keratinocytes, hepatocytes, and blood. iPSCs are similar to embryonic stem cells (ESCs) in several aspects, such as morphology, expression of pluripotency markers, and the ability to develop teratoma that contains tissue from three germ layers. In addition, iPSCs can undergo tridermal differentiation, including hepatic specific lineages. Considering that iPSCs could be a source of hepatocyte regeneration, iPSC-based therapy has been widely implicated in the treatment of liver disease and hepatic regeneration. In the present review, we discuss the therapeutic potential of iPSCs in hepatic repair and focus on the clinical applications of iPSCs.
诱导多能干细胞(iPSCs)通过引入特定因子将体细胞重编程为多能状态而产生。它们可以从不同来源的细胞产生,如成纤维细胞、角质细胞、肝细胞和血液。iPSCs 在多个方面与胚胎干细胞(ESCs)相似,例如形态、多能性标志物的表达以及形成包含三个胚层组织的畸胎瘤的能力。此外,iPSCs 可以进行三胚层分化,包括肝特异性谱系。鉴于 iPSCs 可能是肝细胞再生的来源,基于 iPSC 的治疗已广泛涉及肝脏疾病和肝再生的治疗。在本综述中,我们讨论了 iPSCs 在肝修复中的治疗潜力,并重点介绍了 iPSCs 的临床应用。